

## A new IMAC medium for scaling up purification of Histidine-tagged proteins

**Intellectual Property Notice:** Part of GE Healthcare's Life Sciences business was acquired by Danaher on 31 March 2020 and now operates under the Cytiva<sup>™</sup> brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

#### cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.

Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners. © 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit <a href="https://contact.com/contact">cytiva.com/contact</a>

CY16387-09Sep20-PT

# A new IMAC medium for scaling up purification of Histidine-tagged proteins

Jon Lundqvist, Lars C Andersson, Ann Bergh, Ellinor Ancker, Marianne Carlsson, Anna Heijbel, Helena Lindgren, Karin Torstenson and Katarina Öberg

GE Healthcare, SE-751 84 Uppsala, Sweden

## Introduction

The (Histidine)<sub>6</sub>-tag has become the most used affinity tag due to its small size, strong metal ion binding and ability to bind under denaturing conditions. Immobilized Metal Ion Affinity Chromatography (IMAC) with Ni<sup>2+</sup> is the standard method for purifying histidine-tagged proteins. Here, a new medium optimized for scaling up purification, Ni Sepharose™ 6 Fast Flow, is presented.

## Ni Sepharose 6 Fast Flow

- Pre-charged with Ni<sup>2+</sup> and available in different formats, including pre-packed 1-ml and 5-ml HisTrap<sup>™</sup> FF and 20-ml HisPrep<sup>™</sup> FF 16/10 columns.
- The bead-size (~90-µm) makes it possible to scaleup purification maintaining high target protein concentration in the eluted peak.
- Compatible with a wide range of buffers and additives, including denaturants, detergents and reducing agents.

## Conclusions

The following results were obtained with Ni Sepharose 6 Fast Flow:

- Easy to scale-up purification from 1-ml via 5-ml to 20-ml columns.
- Low leakage of Ni<sup>2+</sup> and compatibility with the reducing agent DTT.
- A number of Histidine-tagged proteins from different:
  - expression systems
  - expression levels
  - with different M<sub>r</sub>
  - with different lengths of the Histidine-tag were easily purified.



## **Material and Methods**

Chromatography conditions were, unless otherwise stated:

0 1	5
Medium:	Ni Sepharose 6 Fast Flow pre-packed in 1-ml and 5-ml HisTrap FF, and 20-ml HisPrep FF 16/10 columns
Samples:	Cell extracts from <i>E. coli</i> or <i>P. pastoris</i> were clarified by centrifugation and filtration; containing 0.5 M NaCl and imidazole at a concentration appropriate for each target protein.
Flow rate:	1 ml/min
Binding buffer:	20 mM sodium phosphate, 0.5 M NaCl, x mM imidazole, pH 7.4 (x = optimized for each target protein)
Ontimization <sup>.</sup>	The optimal imidazole concentration to

- *Optimization:* The optimal imidazole concentration to obtain the best purity and yield differs from protein to protein. A small number of screening runs, including a run with a linear imidazole gradient from 5 mM, will facilitate finding a suitable imidazole concentration for optimal results.
- Elution buffer: 20 mM sodium phosphate, 0.5 M NaCl, 500 mM imidazole, pH 7.4

Purifications were performed on ÄKTAexplorer™ 10 or 100 systems. Elution was done either with a step or a linear imidazole gradient. SDS-PAGE was performed with ExcelGeI™ SDS Gradient 8–18 Gels.

## Purifications of Histidine-tagged proteins in the presence of DTT

Column:	HisTrap FF 1-ml	
Sample:	(Histidine)_e-tagged Maltose Binding Protein in E. coli extract (conc. ~1 mg/ml, M, ~43 000)	
Sample volume: 7 ml		
Binding buffer:	2 or 5 mM DTT, 20 mM sodium phosphate, 25 mM imidazole, 500 mM NaCl, pH 7.4	
Elution buffer:	2 or 5 mM DTT, 20 mM sodium phosphate, 500 mM imidazole, 500 mM NaCl, pH 7.4	
Flow rate:	1 ml/min	

Note: A blank run without DTT was performed before the sample application.





Fig 1. Purity and recovery of repeated purification runs on Ni Sepharose 6 Fast Flow without  ${\rm Ni}^{2*}$  recharging.

### Results:

• Purity and recovery were not affected by DTT.

## Six repeated purifications

#### without stripping, cleaning or Ni<sup>2+</sup> recharging the column



**Fig 2.** SDS-PAGE analysis under nonreducing conditions of pooled fractions from different runs.

**Table 1.** Summary of purification results from the six repeated purification runs on Ni Sepharose 6 Fast Flow shown in Figure 2.

Run	Amount eluted protein (mg)	Yield (%)	Molar ratio Ni²+/protein
1	7.5	88	0.14
2	7.4	87	0.11
3	7.4	87	0.08
4	7.2	85	0.07
5	7.5	88	0.07
6	7.5	88	0.06

#### **Results:**


- Excellent reproducibility in purity and recovery without the need for stripping, cleaning, or Ni<sup>2+</sup> recharging the medium.
- Low Ni<sup>2+</sup>-leakage during purifications (low leakage minimizes potential problems such as Ni<sup>2+</sup> induced oligomerization and precipitation of target protein, and loss of binding capacity).

## Purification of a low expressed (Histidine)<sub>6</sub>-tagged hydrolase from Pichia pastoris

Column:	HisTrap FF 1-ml
Sample:	Pichia pastoris extract with low expression of a (putative) Saccharomyces cerevisiae hydrolase ( $M_r \sim 34~000$ )
Sample volume:	50 ml (corresponding to 20 g cells)
Binding buffer:	20 mM sodium phosphate, 50 mM imidazole, 500 mM NaCl, pH 7.4
Elution buffer:	20 mM sodium phosphate, 500 mM NaCl, pH 7.4, 25 ml linear gradient, 50–300 mM imidazole
Flow rate:	1 ml/min

## Results:

- High-purity target protein was obtained despite low expression.
- ~ 90% of the target protein applied on the column was recovered.






Fig 3. Black lines in the chromatogram indicate the final pool.

Fig 4. Analysis by SDS-PAGE.


## Two-step purification of a high molecular weight (Histidine)<sub>10</sub>-tagged protein expressed in *E. coli*


Columns:	IMAC: Gel filt	ration (GF):	HisTrap FF 1-ml HiLoad™ 16/60 Superdex™ 200 pg
Sample:	<i>E.coli</i> extract with Histidine-trx-p450, a large (Histidine) <sub>10</sub> -tagged protein ( $M_r \sim 130000$ )		
Sample volume:	50 ml		
Binding buffer:	IMAC:		dium phosphate, dazole, 500 mM NaCl,
Elution buffer:	IMAC:	20 mM sodium phosphate, 500 mM NaCl, pH 7.4 and 500 mM imidazole	
	GF:	20 mM ph 6 mM KCl	osphate, 0.28 M NaCl, pH 7.4
Flow rate:	IMAC: GF:	1 ml/min 0.5 ml/mir	1

### **Results:**

- Three major bands were detected after IMAC purification.
- A very good separation between the contaminants and (His)<sub>10</sub>-trx p450 was obtained by gel filtration.

*Note:* Contaminants after IMAC were truncated forms of (His)<sub>10</sub>-trx-p450 (as determined by N-terminal sequencing, data not shown).





Lane 1: LMW markers Lane 2: Start material, 1:30 Lane 3: Flowthrough IMAC, 1:20 Lane 4: Wash IMAC, 1:10 Lane 5: Pool IMAC,1:10 Lane 6: Pool 2, GF, 1:2 Lane 7: Pool 3, GF, 1:2 Lane 8: Pool 4, GF, 1:2 Lane 9: Pool 1, GF m


**Fig 5.** Two-step purification by IMAC and gel filtration. SDS-PAGE analysis under reduced conditions.


## Purification of (Histidine)<sub>6</sub>-tagged protein on a 20-ml HisPrep FF 16/10 column

Column: Sample:	HisPrep FF 16/10, 20-ml (Histidine) <sub>e</sub> -tagged Green Fluorescent Protein (GFP-(His) <sub>e</sub> , M <sub>r</sub> ~28 000) in <i>E. coli</i> extract
Sample volume:	230 ml
Binding buffer:	20 mM sodium phosphate, 5 mM imidazole, 500 mM NaCl, pH 7.4
Elution buffer:	20 mM sodium phosphate, 500 mM NaCl, pH 7.4, 500 ml linear gradient, 5–250 mM imidazole
Flow rate:	5 ml/min

### **Results:**

- 0.5 g GFP-(His)<sub>6</sub> was purified on HisPrep FF 16/10.
- GFP-(His)<sub>6</sub> was eluted in 180 ml (conc. 2.7 mg/ml).





**Fig 6.** Total protein monitored at 280 nm (blue line) and GFP-(His)<sub>6</sub> monitored at 490 nm (green line). Black lines in the chromatogram indicate the fraction and pool collected for SDS-PAGE analysis.

## Scaling up purification of (Histidine),-tagged protein





Fig 7. Scaling up from HisTrap FF 1-ml via HisTrap FF 5-ml to a HisPrep FF 16/10, 20-ml prepacked column. The samples loaded contained approximately 8, 40, and 160 mg MBP-(His)<sub>6</sub> respectively. Yield in milligrams is shown in each chromatogram.



Lane 1: LMW markers Lane 2: Start material Lane 3: Eluted pool, HisTrap FF 1-ml Lane 4: Eluted pool, HisTrap FF 5-ml Lane 5: Eluted pool, HisPrep FF 16/10 20-ml

#### Acknowledgement

$$\begin{split} \mathsf{MBP-(His)}_6 \text{ was provided by Pharmacia Diagnostics, Uppsala, Sweden. \\ \mathsf{GFP-(His)}_6 \text{ was provided by Dr. David Drew, Dept. of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden. \end{split}$$

Fig 8. SDS-PAGE analysis under nonreducing conditions.

#### www.chromatography.amershambiosciences.com

GE Healthcare Amersham Biosciences AB Björkgatan 30 751 84 Uppsala Sweden ÄKTAexplorer, ExcelGel, HiLoad, HisTrap, HisPrep, Sepharose and Superdex are trademarks of GE Healthcare Ltd, a General Electric Company. GE and GE monogram are trademarks of General Electric Company.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your local GE Healthcare representative for the most current information.

Purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues may require a license under US pat 5,284,933 and US pat 5,310,663, including corresponding foreign patents (assigne: Hoffman La Roche, Inc).

© 2005 General Electric Company – All rights reserved.

Amersham Biosciences AB, a General Electric company going to market as GE Healthcare.



## imagination at work

11-0032-78 AA